HRS 5635
Alternative Names: HRS-5635Latest Information Update: 11 Jul 2024
At a glance
- Originator Fujian Shengdi Pharmaceutical
- Class Antivirals; Small interfering RNA
- Mechanism of Action Hepatitis B surface antigen expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hepatitis B
Most Recent Events
- 14 Jun 2024 Phase-II clinical trials in Hepatitis B (Treatment-experienced) in China (SC) (NCT06425341)
- 22 May 2024 Fujian Shengdi Pharmaceutical plans a phase II trial for Hepatitis B (Monotherapy, Combination therapy) in China (SC) (NCT06425341)
- 30 Apr 2023 Phase-I clinical trials in Hepatitis B in China (Parenteral, Injection) (NCT05808374)